Overview

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

Status:
Completed
Trial end date:
2019-04-16
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo
Phase:
Phase 3
Details
Lead Sponsor:
Medy-Tox
Treatments:
Botulinum Toxins, Type A